H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Hookipa Pharma to $6.50 from $8 and keeps a Buy rating on the shares post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HOOK:
- Hookipa Pharma reports Q2 EPS (22c), consensus (21c)
- HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Is HOOK a Buy, Before Earnings?
- HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
- Biotech Alert: Searches spiking for these stocks today